YOLFTbeta
Spago Nanomedical AB

Spago Nanomedical AB

SPAGO · ST · Healthcare / Biotechnology

0.045SEK-0.00 (-0.44%)

Price History

Full chart

Market Stats

Previous Close0.0452
Open0.0464
Day Range0.0438 – 0.0466
52-Week Range0.08 – 0.37
Volume91.53K
Market Cap89.02M
P/E (TTM)0.00
Forward P/E4.68
EPS-0.04
Dividend Yield0.00%
Beta1.30
50-Day Avg0.1092
200-Day Avg0.1155

About

Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014. The company was incorporated in 1999 and is based in Lund, Sweden.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Mats Hansen M.Sc., Ph.D.
  • Employees6
  • HeadquartersScheelevAegen 22, Lund, Sweden, 223 63, Sweden
  • Websitehttps://spagonanomedical.se

Leadership

  • Dr. Mats Hansen M.Sc., Ph.D.Chief Executive Officer · b. 1971
  • Ms. Hanna Olsson M.Sc.Chief Financial Officer · b. 1980
  • Mr. Paul HargreavesChief Development Officer · b. 1969

Financials

Income Statement

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue981.00K222.00K228.00K54.00K7.51M58.00K47.00K29.64M30.00K342.00K660.00K1.05M1.20M1.91M437.00K
Growth (%)--77.37%+2.70%-76.32%+13816.67%-99.23%-18.97%+62972.34%-99.90%+1040.00%+92.98%+59.70%+14.14%+58.85%-77.13%
Cost of Revenue-3.67M-4.49M-3.53M-4.91M-5.22M-7.03M-8.37M-8.64M-2.62M758.00K17.44M16.66M24.49M14.27M19.82M
Gross Profit4.65M4.71M3.76M4.96M12.74M7.09M8.42M38.29M2.65M-416.00K-16.78M-15.60M-23.28M-12.36M-19.38M
Gross Margin473.70%2121.62%1649.12%9183.33%169.51%12222.41%17912.77%129.16%8843.33%-121.64%-2541.82%-1480.46%-1935.41%-646.68%-4435.47%
Operating Expense5.36M8.27M8.80M10.83M25.10M14.40M17.50M49.38M22.80M18.55M22.42M23.86M23.95M21.36M11.48M
Operating Income-715.00K-3.56M-5.04M-5.88M-12.36M-7.31M-9.09M-11.09M-20.14M-18.96M-39.19M-39.47M-47.23M-33.71M-30.86M
Operating Margin-72.88%-1604.50%-2212.28%-10879.63%-164.43%-12598.28%-19331.91%-37.42%-67140.00%-5544.44%-5938.18%-3744.31%-3926.27%-1764.15%-7062.70%
EBITDA-545.00K-3.33M-4.70M-5.60M-12.33M-7.02M-8.91M-10.72M-19.73M-18.59M-38.69M-38.73M-42.22M-33.40M-26.39M
EBITDA Margin-55.56%-1500.90%-2059.65%-10374.07%-164.13%-12110.34%-18961.70%-36.15%-65766.67%-5436.26%-5862.27%-3674.48%-3509.89%-1747.83%-6038.22%
Net Income-715.00K-4.62M-5.21M-6.13M-6.79M-7.54M-9.46M-11.09M-20.28M-18.90M-39.08M-39.31M-42.22M-32.51M-26.55M
Net Income Margin-72.88%-2078.83%-2286.84%-11353.70%-90.37%-13000.00%-20121.28%-37.42%-67600.00%-5527.19%-5920.45%-3729.51%-3509.81%-1701.15%-6076.43%
R&D----407.00K3.11M9.24M19.83M2.39M3.34M18.81M17.10M24.49M14.27M11.48M
R&D as % of Total Revenue----5.42%5367.24%19657.45%66.88%7963.33%976.02%2850.30%1622.30%2035.41%746.68%2627.23%
Interest Expense1.00K1.05M332.00K301.00K250.00K251.00K265.00K000121.00K268.00K-00
Interest Expense % of Total Revenue0.10%474.32%145.61%557.41%3.33%432.76%563.83%0.00%0.00%0.00%18.33%25.43%-0.00%0.00%

Balance Sheet

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets25.27M53.61M57.87M75.58M74.73M80.06M111.59M126.32M140.54M162.82M191.62M205.95M52.98M39.58M36.68M
Total Liabilities12.42M11.36M19.69M19.53M9.33M8.22M3.81M4.10M2.91M3.15M6.81M8.80M11.67M6.35M5.94M
Total Equity12.84M42.25M37.04M52.63M65.36M71.84M107.78M122.22M137.63M159.67M184.81M197.16M41.32M33.23M30.75M
Cash1.34M21.98M7.94M14.48M21.51M16.77M30.31M16.47M12.15M28.45M52.46M62.10M45.22M32.47M29.67M
Total Debt--15.85M15.04M5.79M6.04M---------
Net Debt-1.34M-21.98M7.91M557.00K-15.72M-10.73M-30.31M-16.47M-12.15M-28.45M-52.46M-62.10M-45.22M-32.47M-29.67M

Cash Flow

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-276.00K-601.00K-7.74M-5.95M-5.34M-7.86M-7.73M-10.51M-21.29M-18.77M-35.57M-38.19M-44.91M-34.67M-28.30M
Investing Cash Flow-7.57M-7.69M-6.30M-8.16M-7.15M-10.71M-18.08M-28.87M-18.21M-6.38M-4.63M-3.83M-506.00K-230.00K633.00K
Financing Cash Flow8.90M28.92M-20.66M19.52M14.03M39.36M25.54M35.18M41.45M64.21M51.66M28.53M22.15M24.87M
Capital Expenditure7.57M7.69M6.75M8.16M7.15M10.71M18.11M28.87M18.21M6.38M4.63M3.83M153.00K229.00K28.30M
Free Cash Flow-7.84M-8.29M-14.48M-14.12M-12.49M-18.57M-25.84M-39.38M-39.50M-25.15M-40.20M-42.02M-45.06M-34.90M-28.53M
FCF to OCF2842.39%1379.03%187.18%237.15%233.71%236.21%334.23%374.67%185.56%134.02%113.01%110.03%100.34%100.66%100.81%

Earnings

Report DateApr 28, 2021Aug 24, 2021Nov 10, 2021Feb 2, 2022Apr 26, 2022Aug 24, 2022Nov 8, 2022Feb 2, 2023May 9, 2023Jul 31, 2023Nov 3, 2023Feb 7, 2024May 2, 2024Aug 21, 2024Nov 6, 2024Feb 6, 2025May 7, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate----------------------
EPS Actual-0.18-0.28-0.24-0.27-0.24-0.23-0.11-0.12-0.16-0.09-0.08-0.08-0.03-0.03-0.03-0.02-0.02-0.01-0.01-0.01-0.01-0.01
Surprise----------------------
Timing---Pre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-----

Key Statistics & Ratios

Market Cap89.02M
Enterprise Value43.34M
Trailing P/E0.00
Forward P/E4.68
Price / Sales23.38
Price / Book2.40
EPS-0.04
Book Value0.04
Revenue (TTM)3.81M
Gross Profit (TTM)-8.43M
EBITDA-26.19M
Profit Margin0.00%
Operating Margin-736.68%
Return on Equity-104.60%
Return on Assets-53.57%
Shares Outstanding798.38M
Shares Float282.89M
Beta1.30
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • May 28, 20262044:2039
  • Nov 4, 2025247:175
  • Nov 6, 2023156:149
  • Jun 8, 2022369:364